Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

mHealth app for caregiver instruction in manual therapy for chemotherapy-induced peripheral neuropathy

Award Number: R44CA268678
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/18/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

mHealth app for caregiver instruction in manual therapy for chemotherapy-induced peripheral neuropathy - Chemotherapy-induced peripheral neuropathy (CIPN) is a common cancer treatment side effect that impairs quality of life and daily functioning. Some 30% of chemotherapy recipients are estimated to be living with CIPN at least six months beyond end of treatment, a number sure to grow as the population ages and incidence of chemotherapy treatment grows. Fortunately, in recent years research and practice in the field of Oncology Massage (OM) have demonstrated that specific manual therapy techniques can in fact reduce symptoms of CIPN. However, for the vast majority of cancer survivors at risk, access to such services is very limited due to the very small number of qualified practitioners, as well as cost and organizational constraints. This Phase II project will evaluate outcomes of a caregiver education mobile app that teaches lay caregivers how to use OM-informed massage techniques specific to CIPN in supportive care at home. The program to be tested is called “Peripheral Neuropathy Relief (PNR).” It will deliver accurate information about what CIPN is, how specific manual techniques can help reduce its symptoms, and step-by-step instruction in safe and effective techniques specific to CIPN. If successful, this eHealth app will enable wide dissemination of a family caregiver intervention leading to a major impact on quality of life and functioning for millions of cancer survivors and their family members. Phase II will integrate findings from our Phase I study that used a human-centered design approach in formative research to develop a “minimum viable product (MVP)” (prototype) of the PNR program for usability and feasibility testing. Feasibility was established by caregivers’ high usability scores and ratings of perceived value and intent to use the app in the caregiving role. Phase II will complete development and then evaluate the app’s impact on CIPN patients and caregivers in a three-arm randomized controlled trial with 150 patient/partner dyads, comparing PNR to attention control and usual care conditions. Specific aims are as follows: Aim 1. Produce a revised version of the instructional content based on Phase I outcomes. Aim 2. Complete development of the mobile application that will deliver the instructional program and related supplemental materials to patients and caregivers. Aim 3. Assess impact of home-based utilization of the PNR program on cancer survivors with CIPN and caregivers applying the instruction. Hypotheses. (1) In dyads using the PNR intervention, patients will report significant improvements over baseline in CIPN symptom and interference scores; and caregivers will report significant improvements over baseline in caregiver esteem and attitudes toward caregiving for CIPN. (2) Outcomes for dyads in the PNR intervention will be superior to those of the usual care and attention control conditions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,030,459 )
2025	2025	COLLINGE AND ASSOCIATES, INC.	3480 KINCAID ST	EUGENE	OR	97405	LANE	USA	Cancer Cause and Prevention Research	000	3	5/26/2025	NON-COMPETING CONTINUATION	$1,030,459
														Subtotal = $1,030,459

Issue Date FY: 2024 ( Subtotal = $968,308 )
2024	2024	COLLINGE AND ASSOCIATES, INC.	3480 KINCAID ST	EUGENE	OR	97405	LANE	USA	Cancer Cause and Prevention Research	000	2	6/13/2024	COMPETING CONTINUATION	$968,308
														Subtotal = $968,308

Grand Total All Awards = $1,998,767

Top

All Categories

About

Search

Reports

Data Submission

Award Information

mHealth app for caregiver instruction in manual therapy for chemotherapy-induced peripheral neuropathy

Award Number: R44CA268678

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/18/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer